Findings from pivotal nipocalimab Phase 3 study in a broad antibody[...]
Findings from pivotal nipocalimab Phase 3 study in a broad antibody[...]
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
12/12/2024 | Press release | Distributed by Public on 12/12/2024 11:31
Please select the service you want to use:
Smartlinks | GL Events SA | News | Environment | Company News | Securities Issuers | Event Management Companies | London Stock Exchange (LSE) | Frankfurt Stock Exchange | Dusseldorf Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | OTC Markets | Euronext Paris | Cboe BXE Europe | Cboe CXE Europe | Cboe Off Exchange | Aquis Exchange | SIGMA X MTF | Aquis Exchange Europe | Equiduct | Euronext Block MTF | Turquoise
Copyright ©2006-2025 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact